Monoclonal Antibodies and the Treatment of COVID-19

In the treatment of COVID-19, Doylestown Health continues to be on the cutting-edge. A nationwide study, named the BLAZE trial, has seen hospitalizations reduced from 20% to 4.2% when high-risk patients are treated with monoclonal antibody infusions. We are proud to say that our results have mirrored the best in the country. With over 250 patients participating since the beginning of January, the hospitalization rate of patients treated with the drug at Doylestown Hospital is 4.7%.

[@GygaxGirl]

My husband got every side effect listed, the moderate ones. I hope it actually helps him.

[@Kl7714686]

I had this treatment and within 1 hour I could smell again and my symptoms were gone